Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 14 April, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Beta Drugs Ltd

About the Company - Beta Drugs Ltd

Beta Drugs Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24230HP2005PLC028969 and registration number is 028969. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 124.85 Cr. and Equity Capital is Rs. 9.61 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsVillage Nandpur, Lodhimajra Road, Baddi Himachal Pradesh 174101info@betadrugslimited.com
http://www.betadrugslimited.com
Management
NamePosition Held
Mr. Rahul BatraChairperson & Managing Director
Mr. Varun BatraJoint Managing Director
Mr. Balwant SinghWhole Time Director
Mrs. Seema ChopraWhole Time Director
Mr. Ashutosh ShuklaWhole Time Director
Mr. Rohit PartiIndependent Director
Mr. Manmohan KhannaIndependent Director

Beta Drugs Ltd. Share Price Update

Share PriceValue
Today₹1,302.00
Previous Day₹1,304.65

Basic Stock Data of Beta Drugs Ltd

Last Updated: April 8, 2024, 6:04 pm

Market Cap 1,300 Cr.
Current Price 1,352
High / Low1,595/660
Stock P/E37.4
Book Value 148
Dividend Yield0.00 %
ROCE33.9 %
ROE28.6 %
Face Value 10.0

Data Source: screener.in

Competitors of Beta Drugs Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Bliss GVS Pharma Ltd 1,245 Cr. 119150/70.814.2 88.80.42 %11.8 %8.30 % 1.00
RPG Life Sciences Ltd 2,495 Cr. 1,5091,740/73529.4 2030.80 %33.2 %24.2 % 8.00
Ipca Laboratories Ltd 33,971 Cr. 1,3391,348/67066.2 2420.30 %11.2 %8.04 % 1.00
Wanbury Ltd 503 Cr. 154179/33.621.0 6.800.00 %16.9 %% 10.0
Lincoln Pharmaceuticals Ltd 1,200 Cr. 599755/36513.8 2730.25 %21.7 %15.5 % 10.0
Industry Average7,882.80 Cr744.0028.92162.720.35%18.96%11.21%6.00

Beta Drugs Ltd Quarterly Results

MonthSep 2019Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023
Sales474451658896112115141
Expenses3736415168738688108
Operating Profit9811142023272633
OPM %20%19%21%22%23%24%24%23%23%
Other Income000000001
Interest121111111
Depreciation223434565
Profit before tax75791618212027
Tax %27%14%21%30%28%27%25%25%25%
Net Profit54571213161520
EPS in Rs5.334.465.396.8012.2213.6116.4715.4820.67

Last Updated: April 2, 2024, 2:42 am

Beta Drugs Ltd Quarterly Chart

Beta Drugs Ltd Profit & Loss

Last Updated: April 2, 2024, 2:42 am

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales516691116184227256
Expenses41547391141174197
Operating Profit9121825435359
OPM %19%18%20%21%23%23%23%
Other Income0000111
Interest1132223
Depreciation234771011
Profit before tax781216344146
Tax %1%-2%21%27%28%25%
Net Profit78912253135
EPS in Rs7.829.309.8012.1925.8331.9536.15
Dividend Payout %0%0%0%0%0%0%

Beta Drugs Ltd Profit & Loss Yearly Chart

Beta Drugs Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:35%
3 Years:36%
TTM:23%
Compounded Profit Growth
10 Years:%
5 Years:35%
3 Years:48%
TTM:20%
Stock Price CAGR
10 Years:%
5 Years:65%
3 Years:119%
1 Year:90%
Return on Equity
10 Years:%
5 Years:25%
3 Years:27%
Last Year:29%

Beta Drugs Ltd Balance Sheet

Last Updated: April 2, 2024, 2:42 am

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital991010101010
Reserves2432485983113
Borrowings82023172120
Other Liabilities92228314555
Total Liabilities5083107118158198
Fixed Assets131844405563
CWIP1150300
Investments000111
Other Assets35506374102135
Total Assets5083107118158198

Beta Drugs Ltd Reserves and Borrowings Chart

Beta Drugs Ltd Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 1708193023
Cash from Investing Activity -11-21-15-6-22-19
Cash from Financing Activity 5129-8-1-2
Net Cash Flow12-92572

Beta Drugs Ltd Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days10413912810690101
Inventory Days3710410210087106
Days Payable81143119127123139
Cash Conversion Cycle60100111795368
Working Capital Days7510095887088
ROCE %18%21%22%36%34%

Beta Drugs Ltd Financial Efficiency Indicators Chart

Beta Drugs Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters66.68%66.68%66.68%66.71%66.71%66.71%66.71%66.71%66.73%66.73%66.73%66.73%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.29%0.29%0.29%0.29%0.32%0.32%
DIIs0.00%0.27%0.28%0.29%0.29%0.29%0.04%0.04%0.04%0.04%0.02%0.02%
Public33.32%33.06%33.03%33.01%33.00%33.00%32.96%32.96%32.94%32.93%32.93%32.92%
No. of Shareholders5445075426757621,2961,4071,4441,4241,4511,7221,928

Beta Drugs Ltd Shareholding Pattern Chart

No. of Beta Drugs Ltd Shareholders

This stock is not held by any mutual fund

Beta Drugs Ltd ROCE Trend

Beta Drugs Ltd EPS Trend

Beta Drugs Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)31.9525.8212.209.939.30
Diluted EPS (Rs.)31.9525.8212.209.939.30
Cash EPS (Rs.)42.7833.3719.3413.7012.58
Book Value[Excl.RevalReserv]/Share (Rs.)127.8296.0571.3759.4147.31
Book Value[Incl.RevalReserv]/Share (Rs.)127.8296.0571.3759.4147.31
Revenue From Operations / Share (Rs.)236.24191.22120.7994.4576.22
PBDIT / Share (Rs.)56.0545.2026.2619.0514.08
PBIT / Share (Rs.)45.2237.6519.1115.1410.80
PBT / Share (Rs.)42.7035.6816.5912.459.14
Net Profit / Share (Rs.)31.9525.8212.209.799.29
NP After MI And SOA / Share (Rs.)31.9525.8212.209.799.29
PBDIT Margin (%)23.7223.6321.7320.1718.47
PBIT Margin (%)19.1419.6915.8116.0314.16
PBT Margin (%)18.0718.6513.7313.1811.99
Net Profit Margin (%)13.5213.5010.0910.3612.19
NP After MI And SOA Margin (%)13.5213.5010.0910.3612.19
Return on Networth / Equity (%)24.9926.8817.0816.4819.64
Return on Capital Employeed (%)32.1033.2422.0920.6518.62
Return On Assets (%)15.4815.729.978.789.74
Long Term Debt / Equity (X)0.050.120.160.170.17
Total Debt / Equity (X)0.130.170.210.340.44
Asset Turnover Ratio (%)1.271.090.820.791.02
Current Ratio (X)2.031.981.991.531.40
Quick Ratio (X)1.541.521.531.191.11
Inventory Turnover Ratio (X)4.165.704.474.437.19
Interest Coverage Ratio (X)22.3122.8810.437.088.51
Interest Coverage Ratio (Post Tax) (X)13.7214.075.854.646.62
Enterprise Value (Cr.)599.62542.92119.6152.99105.50
EV / Net Operating Revenue (X)2.642.951.030.581.60
EV / EBITDA (X)11.1312.494.742.898.66
MarketCap / Net Operating Revenue (X)2.652.960.990.421.37
Price / BV (X)4.905.891.680.672.21
Price / Net Operating Revenue (X)2.652.960.990.421.37
EarningsYield0.050.040.100.240.08

Beta Drugs Ltd Profitability Ratios (%)

Beta Drugs Ltd Liquidity Ratios

Beta Drugs Ltd Liquidity Ratios (%)

Beta Drugs Ltd Interest Coverage Ratios (%)

Beta Drugs Ltd Valuation Ratios

Fair Value of Beta Drugs Ltd Stock

Fair Value: 1614.73

The stock is undervalued by 19.43% compared to the current price ₹1352

Calculation basis:

  • Fair value = (P/E Ratio * (Return on Equity / 100) * Book Value) * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

*Investments are subject to market risks

Strength and Weakness of Beta Drugs Ltd Stock

StrengthWeakness
  1. The stock has a high average ROCE of 21.83%, which is a positive sign.
  2. The company has higher reserves (70.14 cr) compared to borrowings (17.71 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (141.57 cr) and profit (23.43 cr) over the years.
  1. The stock has a high average Working Capital Days of 86.00, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 78.50, which may not be favorable.

FAQ

What is the latest fair value of Beta Drugs Ltd?

The latest fair value of Beta Drugs Ltd is 1614.73.

What is the Market Cap of Beta Drugs Ltd?

The Market Cap of Beta Drugs Ltd is 1,300 Cr..

What is the current Stock Price of Beta Drugs Ltd as on 13 April 2024?

The current stock price of Beta Drugs Ltd as on 13 April 2024 is 1,352.

What is the High / Low of Beta Drugs Ltd stocks in FY 2024?

In FY 2024, the High / Low of Beta Drugs Ltd stocks is ₹1,595/660.

What is the Stock P/E of Beta Drugs Ltd?

The Stock P/E of Beta Drugs Ltd is 37.4.

What is the Book Value of Beta Drugs Ltd?

The Book Value of Beta Drugs Ltd is 148.

What is the Dividend Yield of Beta Drugs Ltd?

The Dividend Yield of Beta Drugs Ltd is 0.00 %.

What is the ROCE of Beta Drugs Ltd?

The ROCE of Beta Drugs Ltd is 33.9 %.

What is the ROE of Beta Drugs Ltd?

The ROE of Beta Drugs Ltd is 28.6 %.

What is the Face Value of Beta Drugs Ltd?

The Face Value of Beta Drugs Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Beta Drugs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE